When Experience Matters…

Our centers have a long history of peripheral blood mononuclear cell (MNC) collection.  In the early 1980’s, our centers began collecting hematopoietic progenitor cell as starting material for stem cell transplants.  These skills were then leveraged to collect apheresis MNCs to support deployment of a novel dendritic cell-based therapy.  In the current cell therapy market, MNCs, often referred to as leukopaks, are collected by our centers for research and GMP further manufacture source material.  Leukopaks can be mobilized or non-mobilized, fresh, or cryopreserved. Our centers are equipped to collect both autologous or allogeneic leukopaks.